Indian Pharma Market Grows on New Products and Volume Recovery in Q2FY27
The Indian pharmaceutical market showed strong growth in Q2FY27, driven by increased prescription demand, pricing, and new product launches. The anti-obesity drug segment, particularly GLP-1 drugs like semaglutide and tirzepatide, saw significant expansion, with generics gaining market share following patent expiries. Chronic therapies, including cardiac, anti-diabetic, and oncology treatments, contributed notably to the market's 12-13.5% value growth, supported by volume recovery and sustained demand across various therapy areas.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 40/100.
Outlets measured: thefinancialexpress, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 8 Oct, 12:00 pm. Other outlets followed.